Quantitative therapy response assessment by volumetric iodine-uptake measurement

• Verfasst von: Dai, Xu [VerfasserIn]
• Verfasst von: Schlemmer, Heinz-Peter [VerfasserIn]
• Verfasst von: Schmidt, Bernhard [VerfasserIn]
• Verfasst von: Höh, Karolin Julia [VerfasserIn]
• Verfasst von: Xu, Ke [VerfasserIn]
• Verfasst von: Ganten, Tom M. [VerfasserIn]
• Verfasst von: Ganten, Maria-Katharina [VerfasserIn]
• Titel: Quantitative therapy response assessment by volumetric iodine-uptake measurement
• Titelzusatz: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib
• Verf.angabe: Xu Dai, Heinz-Peter Schlemmer, Bernhard Schmidt, Karolin Höh, Ke Xu, Tom M. Ganten, Maria-Katharina Ganten
• Jahr: 2013
• Jahr des Originals: 2012
• Umfang: 8 S.
• Teil: volume:82
• Teil: year:2013
• Teil: number:2
• Teil: pages:327-334
• Teil: extent:8
• Fussnoten: Available online: 11 December 2012 ; Gesehen am 02.06.2021
• Titel Quelle: Enthalten in: European journal of radiology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1990
• Jahr Quelle: 2013
• Band/Heft Quelle: 82(2013), 2, Seite 327-334
• ISSN Quelle: 1872-7727
• DOI: doi:10.1016/j.ejrad.2012.11.013
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: CT density
• Sach-SW: DECT
• Sach-SW: Hepatocellular carcinoma
• Sach-SW: Response evaluation
• Sach-SW: Sorafenib
• Sach-SW: Volumetric iodine-uptake
• K10plus-PPN: 1759422673

Abstract

Objectives - To investigate the volumetric iodine-uptake (VIU) changes by dual-energy CT (DECT) in assessing the response to sorafenib treated hepatocellular carcinoma (HCC) patients, compared with AASLD (American Association for the Study of Liver Diseases) and Choi criteria. - Materials and methods - Fifteen patients with HCC receiving sorafenib, monitored with contrast-enhanced DECT scans at baseline and a minimum of one follow-up (8-12 weeks) were retrospectively evaluated. 30 target lesions in total were analyzed for tumor response according to VIU and adapted Choi criteria and compared with the standard AASLD. - Results - According to AASLD criteria, 67% target lesions showed disease control: partial response (PR) in 3% and stable disease (SD) in 63%. 33% lesions progressed (PD). Disease control rate presented by VIU (60%) was similar to AASLD (67%) and Choi (63%) (P>0.05). For disease control group, change in mean VIU was from 149.5±338.3mg to 108.5±284.1mg (decreased 19.1±42.9%); and for progressive disease group, change in mean VIU was from 163.7±346.7mg to 263.9±537.2mg (increased 230.5±253.1%). Compared to AASLD (PR, 3%), VIU and Choi presented more PR (33% and 30%, respectively) in disease control group (P<0.05). VIU has moderate consistency with both AASLD (kappa=0.714; P<0.005) and Choi (kappa=0.648; P<0.005), while VIU showed a better consistency and correlation with AASLD (kappa=0.714; P<0.005; r=0.666, P<0.005) than Choi with AASLD (kappa=0.634, P<0.005; r=0.102, P=0.296). - Conclusion - VIU measurements by DECT can evaluate the disease control consistent with the current standard AASLD. Measurements are semi-automatic and therefore easy and robust to apply. As VIU reflects vital tumor burden in HCC, it is likely to be an optimal tumor response biomarker in HCC.